Financial Performance - The company's operating revenue for Q1 2019 was ¥951,424,447.25, a decrease of 19.04% compared to the same period last year[9]. - The net profit attributable to shareholders was a loss of ¥53,822,598.25, representing a decline of 344.32% year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥58,545,557.81, a decrease of 3,730.68% compared to the previous year[9]. - The basic earnings per share for the reporting period was -¥0.07, a decline of 333.33% year-on-year[9]. - The diluted earnings per share for the reporting period was also -¥0.07, reflecting the same percentage decline[9]. - The net loss for Q1 2019 was CNY 106,143,768.09, compared to a net profit of CNY 10,577,807.94 in Q1 2018, indicating a significant decline in profitability[44]. - The total comprehensive loss for Q1 2019 was CNY 106,143,768.09, compared to a comprehensive income of CNY 10,577,807.94 in Q1 2018[45]. Cash Flow - The net cash flow from operating activities was ¥190,287,700.15, an increase of 307.43% compared to the same period last year[9]. - Total cash inflow from operating activities reached ¥1,132,989,093.41, up from ¥991,032,609.52 year-on-year, indicating a growth of approximately 14.3%[51]. - Cash outflow for purchasing goods and services decreased to ¥500,456,700.16 from ¥761,691,154.45, reflecting a reduction of about 34.3%[51]. - The company reported a net cash flow from financing activities of ¥395,606,649.64, compared to ¥193,202,808.51 in the previous year, marking an increase of approximately 104.5%[52]. - Cash and cash equivalents at the end of the period totaled ¥430,620,316.63, an increase from ¥335,058,231.37 year-on-year, representing a growth of about 28.5%[52]. - The total cash outflow from investment activities was ¥524,041,657.03, which is higher than the previous year's outflow of ¥314,938,755.74, indicating an increase of approximately 66.5%[51]. - The net cash flow from investment activities was negative at -¥523,289,241.33, worsening from -¥310,920,617.89 year-on-year, reflecting an increase in cash outflow of approximately 68.4%[51]. Assets and Liabilities - The total assets at the end of the reporting period were ¥7,064,356,668.40, an increase of 8.35% from the end of the previous year[9]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,787,171,545.12, a decrease of 4.36% compared to the previous year[9]. - Total current assets decreased slightly to CNY 2,554,809,744.39 from CNY 2,556,652,456.41, a decline of 0.06%[33]. - Total non-current assets increased to CNY 4,509,546,924.01 from CNY 3,963,092,748.89, an increase of 13.8%[33]. - Total liabilities increased to CNY 5,171,196,886.95 from CNY 4,496,843,464.54, an increase of 15%[34]. - The company's total equity decreased to CNY 1,893,159,781.45 from CNY 2,022,901,740.76, a decrease of 6.4%[35]. Operational Changes - The company announced a temporary production suspension for its subsidiary, which was disclosed on March 28 and March 30, 2019[21]. - The company reported non-recurring gains and losses totaling ¥4,722,959.56 for the reporting period[10]. - Research and development expenses for Q1 2019 amounted to CNY 18,857,482.39, indicating ongoing investment in innovation despite financial losses[43]. Share Repurchase - The company repurchased 9,869,102 shares, accounting for 1.27% of the total share capital, with a total transaction amount of approximately 39.99 million yuan[19]. - The highest transaction price for the repurchased shares was ¥4.760 per share, while the lowest was ¥3.560 per share[22].
澳洋健康(002172) - 2019 Q1 - 季度财报